Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study to evaluate the effect of IPI-549 in combination of Opdivo in checkpoint inhibitor-naive advanced urothelial cancer patients

Trial Profile

A phase 2 study to evaluate the effect of IPI-549 in combination of Opdivo in checkpoint inhibitor-naive advanced urothelial cancer patients

Planning
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs IPI 549 (Primary) ; Nivolumab (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms MARIO-275
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2018 New trial record
    • 05 Nov 2018 According to a Bristol-Myers Squibb Pharmaceuticals media release, the company in collaboration with Infinity Pharmaceuticals plans to initiate this study in first half of 2019.
    • 05 Nov 2018 According to an Infinity Pharmaceuticals media release, the company plans to initiate this study in collaboration with Bristol-Myers Squibb .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top